Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CELU with free AI briefings, catalyst countdowns, and dilution alerts.

CELU · Celularity Inc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$586,000 Cash on Hand
CF+ Cash Runway
Follow CELU by email Get an email when CELU reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CELU, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Aldesleukin Metastatic HER2 Positive Gastroesophageal Junction Cancer Phase 1/2 · NCT05207722 Terminated
PDA001 Rheumatoid Arthritis Phase 2 · NCT01261403 Terminated
PDA-002 Peripheral Arterial Disease Phase 2 · NCT02264288 Terminated
Human Placenta-Derived Cells PDA001 Intravenous… Stroke, Acute Phase 2 · NCT01310114 Terminated
Fludarabine Metastatic HER2 Positive Gastroesophageal Junction Cancer Phase 1/2 · NCT05207722 Terminated
Allogeneic CD16-expressing Natural Killer Cells… Metastatic HER2 Positive Gastroesophageal Junction Cancer Phase 1/2 · NCT05207722 Terminated
Taniraleucel (CYNK-001) Astrocytoma, Grade IV Phase 1/2 · NCT05218408 Withdrawn

Also used in these trials (approved or third-party drugs, not CELU's own candidates): Mesna, Trastuzumab, Pembrolizumab, Cyclophosphamide, Human recombinant Interleukin-2 (rhIL-2), rhIL-2.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CELU holds $586,000 in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 7 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CELU files for a raise →

👥 Who Owns CELU

Insiders 13.1% Other 5%+ holders 46.1% Institutions 40.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
Lim Kok Thay Institution (13G, 5%+) 14,138,161 43.57% 2025-07-24
PHILIP & DANIELE BARACH FAMILY TRUST 5%+ holder (13D) 11,940,187 36.79% 2026-09-23
PHILP & DANIELE BARACH FAMILY TRUST 5%+ holder (13D) 3,012,048 9.28% 2025-12-19
Robert J Hariri
Chief Executive Officer, Director
Insider 2,853,553 8.79% 2026-04-13
Diane L. Parks
Director · +518,774 options
Insider 520,021 1.60% 2026-01-12
Peter Diamandis
Director · +518,774 options
Insider 394,150 1.21% 2026-01-12
Geoffrey M.D. Ling
Director · +1.49M options
Insider 256,026 0.79% 2026-01-12
Vincent LeVien
Director · +342,586 options
Insider 153,847 0.47% 2026-01-12
John R Haines
Senior Exec Vice President
Insider 30,179 0.09% 2026-04-13
David C Beers
Chief Financial Officer · +1,025 options
Insider 18,201 0.06% 2025-04-13
Stephen Brigido
Pres., Functional Regeneration
Insider 9,474 0.03% 2026-04-13

Share count 32,450,679 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CELU picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CELU and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.